 GPT Infraprojects Ltd receives order worth Rs. 195 crore
GPT Infraprojects Ltd receives order worth Rs. 195 crore Acknit Industries Ltd to close operations at Unit 1 in Falta Special Economic Zone
Acknit Industries Ltd to close operations at Unit 1 in Falta Special Economic Zone Bhagyanagar India Ltd Q2FY26 consolidated PAT higher at Rs. 11.27 crores
Bhagyanagar India Ltd Q2FY26 consolidated PAT higher at Rs. 11.27 crores Zen Technologies Ltd Q2 FY2025-26 consolidated profit increases QoQ to Rs. 59.39 crores
Zen Technologies Ltd Q2 FY2025-26 consolidated profit increases QoQ to Rs. 59.39 crores Seshasayee Paper and Boards Ltd consolidated Q2FY26 PAT up QoQ at Rs. 22.41 crores
Seshasayee Paper and Boards Ltd consolidated Q2FY26 PAT up QoQ at Rs. 22.41 crores 
              Bharat Biotech today announced that the World Health Organization (WHO) has awarded prequalification to its rotavirus vaccine, ROTAVAC 5D®. The new variant of ROTAVAC®, ROTAVAC 5D®, is a unique rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children.
WHO Prequalification enables the procurement of ROTAVAC 5D® by UN agencies namely UNICEF and PAHO. It is a validation of the global quality and safety standards required for pediatric vaccines. WHO prequalification of ROTAVAC 5D® will fast-track global access to this life saving vaccine.
Mrs. Suchitra Ella, Joint Managing Director, Bharat Biotech, said, "ROTAVAC® and ROTAVAC 5D® are projects conceived, innovated, and executed in India; in collaboration with Indian and Global partners. This is the culmination of a 30 year effort to develop a novel rotavirus vaccine, resulting in a major advancement in Rotavirus disease prevention and reasserts India's leadership in developing and introducing rotavirus vaccines for the world. Today's announcement is an important step to further strengthen and fulfill Bharat Biotech's vision to address neglected diseases and prevent infections that continue to affect millions in the developing world."
Bharat Biotech developed the first generation, rotavirus vaccine, ROTAVAC® under a Public-Private Partnership with the Department of Biotechnology, Government of India and 16 other international partners, making it the largest ever social innovation project for public health. In the developing world, ROTAVAC® has been instrumental in addressing deaths due to rotavirus infection. Bharat Biotech has so far supplied more than 250 million doses of ROTAVAC®.
Rotavirus is the leading cause of severe diarrhea among children less than five years of age around the world, resulting in more than 200,000 deaths and 2 million hospitalizations worldwide. Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals of UNDP.